摘要
目的探讨microRNA-224-3p(miR-224-3p)在结直肠癌患者血清中的表达及临床意义。方法采用荧光定量PCR(SYBRGreen法)检测miR-224-3p在50例结直肠癌患者和44例健康者(健康对照组)血清中的表达量。结果血清miR-224-3p在健康对照组中的相对表达量中位数(四分位数)为1.04(0.80~1.40),在结直肠癌组中相对表达量为2.01(0.92~3.05),差异有统计学意义(P<0.05)。对结直肠癌患者的病理参数进行进一步分析发现,血清miR-224-3p在癌胚抗原(CEA)<10ng/mL的分组中相对表达量中位数(四分位数)为1.47(0.84~2.56),在CEA>10ng/mL的分组中相对表达量为2.96(2.22~3.39),差异有统计学意义(P<0.05),miR-224-3p和CEA联合检测,可以提高诊断的准确性。血清miR-224-3p在不同预后情况以及CEA表达水平中差异有统计学意义(P<0.05),提示血清miR-224-3p可用于结直肠癌患者的预后判断。结论在结直肠癌患者的血清中,miR-224-3p的表达量高于健康者,与CEA联合检测,有望用于结直肠癌的辅助诊断,也可用于结直肠癌的预后判断。
Objective To investigate the expression of microRNA-224-3p (miRNA-224-3p) in serum of patients with colorectal cancer and its clinical significance.Methods Fluorescence quantitative PCR (SYBR Green method) was used to detect the expression of miRNA-224-3p in serum of 50 patients with colorectal cancer and 44 healthy persons (healthy control group).Results The relative expression of serum miRNA-224-3p was 1.04 (0.80-1.40) in healthy control group and 2.01 (0.92-3.05) in colorectal cancer group,with significant difference ( P <0.05).Further analysis of the pathological parameters of colorectal cancer group showed that the relative expression of serum miR-224-3p was 1.47(0.84-2.56) in the group of CEA<10 ng/mL and 2.96(2.22-3.39) in the group of CEA>10 ng/mL,the difference was statistically significant( P <0.05).The combined detection of miR-224-3p and CEA could improve the accuracy of diagnosis.Serum miR-224-3p had significant difference in the different prognosis group and CEA expression level ( P <0.05),suggesting that serum microRNA-224-3p could be used to predict the prognosis of colorectal cancer patients.Conclusion In the serum of patients with colorectal cancer,the expression of miRNA-224-3p is higher than that of healthy people,so the combined detection of miR-224-3p and CEA was expected to be used for assistant diagnosis of colorectal cancer.Serum miR-224-3p can also be used to judge the prognosis of colorectal cancer.
作者
朱莹
王亚南
ZHU Ying;WANG Yanan(Department of Clinical Laboratory,Suzhou Municipal Hospital,Suzhou,Jiangsu 215000,China;Department of Pathology,Suzhou Ninth People′sHospital,Suzhou,Jiangsu 215000,China;Department of Clinical Laboratory,Suzhou Hospital Affiliated to Nanjing Medical University,Suzhou,Jiangsu 215002,China)
出处
《国际检验医学杂志》
CAS
2019年第13期1548-1552,共5页
International Journal of Laboratory Medicine
基金
苏州市“科教兴卫”青年科技项目(KJXW2014017)
